1. Home
  2. HBB vs ENGN Comparison

HBB vs ENGN Comparison

Compare HBB & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hamilton Beach Brands Holding Company

HBB

Hamilton Beach Brands Holding Company

HOLD

Current Price

$32.07

Market Cap

418.3M

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$1.92

Market Cap

117.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBB
ENGN
Founded
1904
1999
Country
United States
Canada
Employees
660
N/A
Industry
Home Furnishings
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
418.3M
117.2M
IPO Year
2017
2023

Fundamental Metrics

Financial Performance
Metric
HBB
ENGN
Price
$32.07
$1.92
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$21.08
AVG Volume (30 Days)
69.0K
667.0K
Earning Date
05-06-2026
06-11-2026
Dividend Yield
2.38%
N/A
EPS Growth
N/A
56.85
EPS
2.75
N/A
Revenue
$606,852,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.52
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.56
$1.40
52 Week High
$34.26
$12.25

Technical Indicators

Market Signals
Indicator
HBB
ENGN
Relative Strength Index (RSI) 61.71 56.43
Support Level $29.49 $1.67
Resistance Level $34.19 $1.95
Average True Range (ATR) 1.30 0.07
MACD -0.16 0.01
Stochastic Oscillator 93.98 88.89

Price Performance

Historical Comparison
HBB
ENGN

About HBB Hamilton Beach Brands Holding Company

Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products segment includes consumer product revenue consisting of sales of small electric household and specialty housewares appliances whereas the health segment includes lease revenue associated with leases of connected devices to specialty pharmacy networks and pharmaceutical companies, as well as licensing revenue which grant customers the right to use software for healthcare management.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: